Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus CLINISOL 15 SULFITE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus CLINISOL 15 SULFITE FREE IN PLASTIC CONTAINER.
AMINOSYN-HBC 7% IN PLASTIC CONTAINER vs CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
Provides essential amino acids and calories for protein synthesis and energy metabolism in parenteral nutrition.
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
Intravenous infusion: 1.5 g/kg/day (amino acids) as part of parenteral nutrition; typical infusion rate 0.8-1.5 g/kg/hr.
None Documented
None Documented
Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand.
Amino acids have variable individual half-lives; the terminal elimination half-life for the amino acid mixture is approximately 1.5–2 hours, reflecting rapid distribution and metabolism; clinically, cessation of infusion leads to rapid decline in plasma amino acid levels.
Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination.
Renal (primarily as amino acids and metabolites); >90% of infused amino acids are eliminated via renal excretion as nitrogenous waste (urea, ammonia) and oxidized to CO2 and water; <10% excreted unchanged in bile/feces.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution